Skip to main content

Obesity drug Wegovy's landmark trial result could 'open up' health insurance access, analyst says

Popular weight-loss drug Wegovy could be made available under more health insurance schemes after the results of a late-stage trial pointed to the drug's efficacy in reducing cardiovascular events, analysts said Wednesday.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.